MAIA Biotechnology Files Q1 2025 10-Q
Ticker: MAIA · Form: 10-Q · Filed: May 9, 2025 · CIK: 1878313
Sentiment: neutral
Topics: 10-Q, biotechnology, financing, licensing
TL;DR
MAIA Bio Q1 10-Q filed. Updates on UT Southwestern deal, private placements, and ATM offerings.
AI Summary
MAIA Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details on its "University of Texas Southwestern" patent and technology license agreement. The filing also mentions subsequent events such as a private placement and a registered direct offering.
Why It Matters
This filing provides investors with an update on MAIA Biotechnology's financial health and strategic developments during the first quarter of 2025.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry higher risk due to the nature of drug development and regulatory hurdles.
Key Numbers
- $1M — Net Sales (Reported as up to one million)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Filer of the 10-Q
- University of Texas Southwestern (company) — Subject of a patent and technology license agreement
- 20250331 (date) — End of the reporting period
- 20250509 (date) — Filing date
- 001-41455 (dollar_amount) — SEC File Number
FAQ
What were the key financial highlights for MAIA Biotechnology in Q1 2025?
The filing does not provide specific dollar amounts for revenue or expenses for Q1 2025, but it does mention 'NetSalesUptoOneMillionMember'.
What is the status of the patent and technology license agreement with the University of Texas Southwestern?
The 10-Q filing references a 'PatentAndTechnologyLicenseAgreementMember' with the 'UniversityOfTexasSouthwesternMember', indicating ongoing activity related to this agreement.
Did MAIA Biotechnology engage in any equity offerings during the reporting period?
Yes, the filing mentions 'AtTheMarketEquityOfferingMember' and 'RegisteredDirectOfferingMember' for the period ending March 31, 2025.
Are there any significant subsequent events mentioned in the filing?
Yes, the filing notes 'us-gaap:SubsequentEventMember' including a 'us-gaap:PrivatePlacementMember' that occurred on '2025-05-09'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st ('1231').
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding MAIA Biotechnology, Inc. (MAIA).